How India Exports Natural to the World

In the United States, the FDA's Orange Book lists approved drug products, including those under HS Code 30049011. The approval of Abbreviated New Drug Applications (ANDAs) for these products indicates their compliance with FDA standards for safety and efficacy. The presence of 283 active Indian exporters underscores the significance of this market segment.

The FDA's regulatory pathway for these products involves a thorough review process to ensure therapeutic equivalence to reference listed drugs (RLDs). The Orange Book provides detailed information on RLDs and reference standards, facilitating the approval process for generic versions. Import alerts are issued when products fail to meet FDA requirements, emphasizing the need for exporters to maintain stringent quality standards.

In the European Union, the European Medicines Agency (EMA) oversees the marketing authorization of medicinal products. Products under HS Code 30049011 must comply with EU Good Manufacturing Practice (GMP) requirements to ensure quality and safety. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates these products, requiring adherence to UK GMP standards.

The World Health Organization (WHO) includes certain traditional medicines in its Model List of Essential Medicines, recognizing their importance in healthcare systems. Inclusion in the WHO Prequalification Programme signifies compliance with global quality standards. Additionally, adherence to pharmacopoeia standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) is crucial for international acceptance.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies medicinal products under various schedules. Products under HS Code 30049011 are typically classified under Schedule H, requiring a prescription for sale. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of these products under the Drug Price Control Order (DPCO). Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for exporting these products.

The patent status of products under HS Code 30049011 varies depending on the specific formulation and active ingredients. Generic competition is influenced by the expiration of patents and exclusivity periods, as listed in the FDA's Orange Book. Monitoring these statuses is essential for market entry strategies.

In June 2025, the NPPA revised the ceiling prices for several Ayurvedic formulations, impacting products under HS Code 30049011. In September 2025, the CDSCO issued new guidelines for the export of traditional medicines, emphasizing quality control measures. In December 2025, the WHO updated its Model List of Essential Medicines to include additional traditional medicines, reflecting their growing importance. In February 2026, the FDA introduced a new framework for the evaluation of traditional medicines, aiming to streamline the approval process. In March 2026, the EMA released a report highlighting the increased demand for traditional medicines in the European market, indicating potential growth opportunities for exporters.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 60–70% of India's API and KSM requirements are imported from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese exports can lead to shortages and increased costs for Indian pharmaceutical manufacturers.

In response, the Indian government has initiated measures to reduce this dependency. In October 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to manufacture critical molecules like Penicillin G, 6-APA, and Clavulanic Acid. These efforts are projected to halve India's import dependence on key pharmaceutical ingredients. However, the transition to self-sufficiency is gradual, and the industry remains susceptible to external supply chain disruptions in the interim.

Analysis of TransData Nexus's proprietary trade data reveals a high supplier concentration in the export of "Natural" from India. The top five exporters account for 62.4% of total exports, with SHALINA LABORATORIES PRIVATE LIMITED alone contributing 17.4% ($4.5 million). Such concentration poses a single-source risk; any operational or financial issues within these key suppliers could significantly disrupt the supply chain.

To mitigate this risk, the Indian government has implemented the PLI scheme to encourage diversification and bolster domestic production capabilities. While these initiatives are steps toward reducing dependency on a limited number of suppliers, the current landscape still reflects a substantial concentration risk that necessitates ongoing monitoring and strategic planning.

Recent geopolitical tensions have further strained global supply chains. In February 2026, the U.S. and Israel launched "Operation Epic Fury" against Iran, leading to Iran's blockade of the Strait of Hormuz—a critical maritime chokepoint through which approximately 20% of global oil passes. This blockade has disrupted shipping routes, causing delays and increased costs for industries reliant on maritime transport, including pharmaceuticals. (lemonde.fr)

Additionally, the Red Sea and the Suez Canal have experienced instability due to attacks by Iran-backed Houthi forces, compelling shipping companies to reroute vessels around Africa's Cape of Good Hope. This detour adds approximately 10 to 14 days to transit times, further exacerbating supply chain challenges. These disruptions have led to increased freight rates and potential shortages of critical pharmaceutical products, underscoring the need for resilient and diversified supply chain strategies.

• Diversify Supplier Base: Expand the network of API and KSM suppliers beyond China to include other countries and domestic manufacturers, reducing dependency on a single source.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to boost local manufacturing of critical pharmaceutical ingredients.

• Strengthen Supply Chain Resilience: Develop contingency plans and maintain strategic stockpiles to buffer against geopolitical disruptions affecting key shipping routes.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could impact supply chains, enabling proactive risk management.

• Invest in Alternative Logistics: Explore and invest in alternative transportation methods, such as air freight or overland routes, to circumvent maritime chokepoints during crises.

RISK_LEVEL: HIGH